Aardvark Therapeutics (AARD) Non Operating Investment Income (2024 - 2026)
Aardvark Therapeutics (AARD) posted Non Operating Investment Income of -$13000.0 for Q1 2026, up 31.58% sequentially from -$19000.0 in Q4 2025, and up 13.33% YoY from -$11470.6 in Q1 2025.
Aardvark Therapeutics (AARD) Non Operating Investment Income (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Non Operating Investment Income for 3 years, with the latest figure at -$13000.0 in Q1 2026.
- Quarterly Non Operating Investment Income rose 13.33% year-over-year to -$13000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3000.0 (up 97.54% YoY) and the FY2025 annual result came in at -$5000.0, up 97.7% from the prior year.
- Non Operating Investment Income improved to -$13000.0 in Q1 2026 per AARD's latest filing, from -$19000.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $36000.0 in Q3 2025 and troughed at -$110000.0 in Q1 2024.
- A 3-year average of -$26111.1 and a median of -$15000.0 in 2025 frame the typical range for Non Operating Investment Income.
- The widest YoY moves for Non Operating Investment Income: up 139.56% in 2025, down 123.33% in 2025.
- Over 3 years, Non Operating Investment Income stood at -$46000.0 in 2024, then soared by 58.7% to -$19000.0 in 2025, then soared by 31.58% to -$13000.0 in 2026.
- According to Business Quant data, Non Operating Investment Income over the past three periods registered -$13000.0, -$19000.0, and $36000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | -13,000.00 |
| Mar 31, 2026 | -13,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Mar 31, 2025 | -15,000.00 |
| Dec 31, 2024 | -46,000.00 |
| Dec 31, 2024 | -46,000.00 |
| Sep 30, 2024 | -91,000.00 |
| Sep 30, 2024 | -91,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Mar 31, 2024 | -110,000.00 |
| Mar 31, 2024 | -110,000.00 |